Feature Channels: Clinical Trials

• share
• favorite_border

Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center — a member of the global Pacific Pediatric Neuro-Oncology Consortium (PNOC) research group — is participating in a PNOC clinical trial for children and young adults with recurrent or progressive high-grade glioma (HGG), an aggressive, fast-growing type of brain tumor. The hospital is one of only 12 centers in the U.S., and the only center in the New York metropolitan area, to offer this trial.

• share
• favorite_border

There is a growing awareness that the design of clinical trials can be misleading and provide evidence that does not end up actually benefiting patients in the clinical setting.

• share
• favorite_border

Karallief® Inc., a leading nutraceutical ingredient company that researches, develops, and distributes clinically studied herbal extract ingredient formulas, announced today that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,364,255 for Karallief® Easy Climb®.

• share
• favorite_border

DETROIT (June 22, 2022) –Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed completely virtual during the COVID-19 pandemic. The novel study design could serve as a model for future research.Unlike traditional clinical trials that involve in-person clinic visits, researchers in this study engaged directly with more than 400 patients through a mobile app and secure website to collect participants’ data and other information.

• share
• favorite_border

An important new study of diverse communities is looking at how brain changes, genetics and other factors contribute to dementia and Alzheimer’s disease. The results could affect millions. Among people 65 and older, about 1 in 9 has Alzheimer’s disease.

• share
• favorite_border

New research in mice from Thomas Jefferson University has paved the way for a Phase I clinical trial and has the potential to transform vaccines against HIV and malaria.

• share
• favorite_border

According to a paper published in Frontiers in Oncology, daily use of a unique mushroom extract AHCC® supported the immune system in clearing HPV infections in two-thirds of study participants after six months of supplementation.

• share
• favorite_border

Daily use of a mushroom extract supported the immune system in clearing human papillomavirus (HPV) infections, according to researchers with UTHealth Houston. The study was published today in Frontiers in Oncology.

• share
• favorite_border

New population study in JNCCN on adjuvant hormone therapy for breast cancer finds correlation between hot flashes and poorer outcomes—in contrast to clinical trial results; likely due to patients with side-effects ending treatment early.

• share
• favorite_border

MD Anderson, Invectys and CTMC announced a strategic collaboration to develop CAR T cell therapies targeting HLA-G for treating solid tumors.

• share
• favorite_border

Researchers at The University of Kansas Cancer Center have released the results of a clinical trial that examined the effectiveness of varenicline in African Americans. In their study published in JAMA, African American daily smokers who were given varenicline while receiving counseling had significantly greater quit rates than those who received a placebo.

• share
• favorite_border

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants taking a placebo.

• share
• favorite_border

A team of researchers from National University of Singapore, in collaboration with clinicians from the National University Cancer Institute, Singapore which is part of the National University Health System, has reported promising results in using CURATE.AI, an artificial intelligence tool that identifies and better allows clinicians to make optimal and personalised doses of chemotherapy for patients.

• share
• favorite_border

A study of the lead agent (CPI-613) in a class of anticancer drugs undergoing Food and Drug Administration (FDA) approved clinical trials reveals that CPI-613 is effective against most carcinoma cell lines, and, used in combination, could have efficacy against reducing some tumors.

• share
• favorite_border

Previous clinical trials have provided insufficient evidence to decide whether testosterone causes heart problems in men during the first year of treatment, according to research being presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga., and published in The Lancet Healthy Longevity.

• share
• favorite_border

Byron Lam and collaborators at the University of Miami reported results from an 8-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy. They found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose.

• share
• favorite_border

The immunotherapy SurVaxM is being utilized in a pilot study in children and adolescents with several brain cancer types through a multicenter trial sponsored by the Pediatric Brain Tumor Consortium (PBTC).

• share
• favorite_border

New research led by Kara Kelly, MD, of Roswell Park Comprehensive Cancer Center and presented today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago shows that a combination of brentuximab vedotin (Bv) and standard chemotherapy is safe and more effective than standard chemotherapy in pediatric patients up to age 21 years with newly diagnosed high-risk Hodgkin lymphoma. The findings from a phase 3 National Cancer Institute-supported multicenter Children’s Oncology Group clinical trial (NCT 02166463) were presented by first author Sharon Castellino, MD, of Emory University and Children’s Healthcare of Atlanta in an oral abstract session on Friday, June 3.

• share
• favorite_border

Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for patients with advanced tumors.

• share
• favorite_border

Experts from Cedars-Sinai Cancer are available to comment on the American Association for Cancer Research (AACR) Cancer Disparities Progress Report 2022, which will be released Wednesday, June 8, in a virtual congressional briefing. The report highlights the need to increase diversity in clinical trials and the cancer workforce, and it provides policy recommendations for addressing cancer disparities—all areas Cedars-Sinai Cancer is working to address.

• share
• favorite_border

On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML), in a talk at the American Society of Clinical Oncology (ASCO) annual meeting 2022.

• share
• favorite_border

Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.

• share
• favorite_border

In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.

• share
• favorite_border

A combination of chemotherapy with an immunotherapy meant to unleash the anticancer capacity of the immune system was effective against one of the hardest targets in cancer care, pancreatic cancer, in a national, randomized clinical trial led by researchers at the Perelman School of Medicine at the University of Pennsylvania, and sponsored by the Parker Institute for Cancer Immunotherapy.

• share
• favorite_border

Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug combination could extend the lives of those diagnosed with advanced non-small cell lung cancer, one of the most common forms of lung cancer. The research was presented today during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, with simultaneous publication in the peer-reviewed Journal of Clinical Oncology.

• share
• favorite_border

Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news.

• share
• favorite_border

Researchers from Roswell Park Comprehensive Cancer Center will present the latest results of clinical trials and insights on cancer treatment and issues affecting patients with cancer, including the financial burdens induced by cancer treatment, at the annual meeting of the American Society of Clinical Oncology (ASCO), which will take place both online and in-person in Chicago, Illinois, from June 3 to 7.

• share
• favorite_border

A University of Miami Miller School of Medicine researcher is hoping an innovative multicenter clinical trial will lead to new therapies for neurofibromatosis type 2 (NF2), a devastating disease causing multiple types of tumors involving the brain, spine, and peripheral nerves.

• share
• favorite_border

Cells produce proteins like little factories. But if they make too much at the wrong times it can lead to diseases like cancer, so they control production with a process called RNA interference (RNAi).

• share
• favorite_border

Researchers at Washington University School of Medicine in St. Louis have developed a way to attack synovial sarcoma — a rare tumor of soft tissues, such as ligaments and muscles — using an investigational drug that triggers cell death.

• share
• favorite_border

Global celebration of 10 years of discovery and lifesaving innovation in immuno-oncology

• share
• favorite_border

Researchers at Saint Louis University School of Medicine are enrolling volunteers in an investigational drug trial for hypogonadal men with chronic kidney disease.

• share
• favorite_border

The 2022 Annual Report from Cedars-Sinai Cancer, which is available now, shines a spotlight on ways this expert team, ranked among the top 10 in the nation for cancer care by U.S. News & World Report, has treated more than 60 types of cancer while honoring and expanding a long-standing commitment to health equity.

• share
• favorite_border

Study found that some drugs were on the market for over five years with no confirmed clinical benefit.

• share
• favorite_border

Indiana University's Amy Knopf can speak about the impacts of a recent National Academies of Sciences, Engineering, and Medicine report, "Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups."

• share
• favorite_border

Susan G. Komen awarded a research grant to apply a new, first-of-its-kind tool that seeks to more accurately diagnose inflammatory breast cancer (IBC).

• share
• favorite_border

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.

• share
• favorite_border

People who are highly responsive to food lost more weight and kept it off using a new weight loss program that targets internal hunger cues and the ability to resist food, reports University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science.

• share
• favorite_border

SEATTLE (May 18, 2022) – Building on momentum from the highly successful COVID-19 vaccine clinical trials, the HIV Vaccine Trials Network (HVTN) is launching a new HIV awareness campaign and unveiling a first-of-its-kind national registry that will provide updated HIV information and make it easier to learn about and participate in HIV clinical trials at HelpEndHIV.org.

• share
• favorite_border

IMpower010 was a randomized, multicenter, open-label, phase 3 study done at 227 sites in 22 countries and regions.

• share
• favorite_border

The Pulmonary Fibrosis Foundation (PFF) has developed new materials and tools for people living with pulmonary fibrosis (PF) to learn about and enroll in clinical research studies.

• share
• favorite_border

University Hospitals’ Jonathan Shoag, MD, and a team of researchers from Case Western Reserve University and the Case Comprehensive Cancer Center, Weill Cornell Medical Center, the Fred Hutchinson Cancer Research Center, and others, set out to assess the tradeoffs of PSA screening using long-term epidemiologic data. “No matter the assumptions,” Shoag said, “the data showed lower numbers than prior estimates, many in the low single digits, for the number needed to treat to prevent a prostate-cancer death. This result was observed in all men, and especially for Black men.” The researchers presented their findings in a late-breaking abstract at the American Urological Association’s annual meeting this month and the study was published May 15 in The New England Journal of Medicine Evidence.

• share
• favorite_border

In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma.

• share
• favorite_border

A novel technology designed to precisely image aggressive brain cancers and guide treatment is being developed by the University of South Australia and Australian cancer diagnostic company, Ferronova, potentially helping thousands of people who are diagnosed with the deadly condition each year.

• share
• favorite_border

A phase 2 clinical trial testing novel immunotherapy combinations in aggressive ovarian cancer has opened and first patients have begun treatment.

• share
• favorite_border

A suite of complimentary tests can quantify changes in dogs suspected of suffering from cognitive decline. The approach could benefit dogs and serve as a model for evaluating cognitive decline progression in – and treatments for – humans with Alzheimer’s disease.